New RT journal calls for papers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts.

Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts. Manuscripts should focus on imaging, contouring, target delineation, simulation, treatment planning, immobilization, organ motion, patient safety, and quality measurement.

W. Robert Lee, MD, has been named editor of Practical Radiation Oncology. Dr. Lee is a professor in the department of radiation oncology and program director of the radiation oncology training program at Duke University in Durham, N.C. Visit ees.elsevier.com/practicalradonc/ to submit a manuscript.

Articles in this issue
PSA test drives diagnosis within families
New RT journal calls for papers
Oral Bisphosphonates Not Linked to Esophageal Cancer Risk
Partnering of chemotherapy and radiation yields great response rates in H&N ca, but has not improved survival
Should radiation therapy plus hormone therapy be the new standard of care for locally advanced prostate cancer?
Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma
Ipilimumab put on fast track by FDA
Who's News
ASTRO releases breast RT guide
Research chair named after Dr. Salem
Breast Cancer Specialists Brace for FDA Word on Avastin
Influx of Funding Impels Collaborative Explorations to Study Sarcoma as Behavior Model for Other Cancers
ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
Study supports earlier colon cancer screening for men, but not African Americans
Bone marrow procedures move into the 21st century

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
2 experts in this video
4 experts in this video
4 experts in this video
2 experts in this video
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
6371178759112
Related Content
104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Rachel Rabinovitch, MD;Julie A. Margenthaler, MD;Fredrik Warnberg;Micheal Leo;Sheila Weinmann;G. Bruce Mann;David J. Dabbs;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer
April 12th 2025
Article
107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka
April 9th 2025
Podcast
Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

Ashley Chan
April 12th 2025
Article

Post hoc analysis of the NAPOLI 3 trial suggests that proactively managing NALIRIFOX-induced diarrhea could allow patients with PDAC to remain on treatment longer.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

Pooja Advani, MBBS, MD;Sofia Braga;Adam M. Brufsky, MD, PhD;Karthik V. Giridhar;Erica L. Mayer, MD, MPH;Kelly E. McCann;Ruth M. O’Regan;Cristina Saura;Seth A. Wander;Georg F. Bischof;Beth H. Lowenthal;Judith D. Bebchuk;Lisa D. Eli;Brian G. Barnett;Joyce A. O’Shaughnessy;Tufia C. Haddad
April 11th 2025
Article
Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

Chemo Effects May Outweigh Obesity-Related GI Alterations in Breast Cancer

Roman Fabbricatore
April 11th 2025
Article

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.